Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 12/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.47 |
| ▸ | PGR | P06401 | 10/20 | 0.47 |
| ▸ | AR | P10275 | 10/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6090891 | 0.85 | NR3C1 (0.49) | NR3C2NR3C1PGRAR | |
| SCHEMBL6091813 | 0.82 | NR3C2 (0.48) | NR3C2NR3C1PGRARJAK2 | |
| SCHEMBL6091165 | 0.82 | NR3C1 (0.53) | NR3C2NR3C1PGRAR | |
| SCHEMBL6089302 | 0.82 | NR3C1 (0.52) | NR3C2NR3C1PGRAR | |
| SCHEMBL6091868 | 0.81 | NR3C2 (0.47) | NR3C2NR3C1PGRARJAK2 | |
| SCHEMBL6091273 | 0.81 | NR3C2 (0.54) | NR3C2NR3C1PGRAR | |
| SCHEMBL6088923 | 0.81 | NR3C2 (0.53) | NR3C2NR3C1PGRAR | |
| SCHEMBL6089546 | 0.80 | NR3C2 (0.46) | NR3C2NR3C1PGRAR | |
| SCHEMBL6090543 | 0.80 | NR3C1 (0.57) | NR3C2NR3C1PGRAR | |
| SCHEMBL6091777 | 0.80 | NR3C1 (0.48) | NR3C2NR3C1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | NR3C2 1/4885NR3C1 4/4885PGR 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.